OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
October 01, 2010
Biopharmaceutical Approvals in the US and EU: A Review
Venture capital is still scarce for early biotechs and their providers.
Can vendor-user partnerships overcome the typical wait-and-see attitude toward new technologies?
Biotech approvals were up last year. Is it a sign of a new trend?
How should the industry educate the public about product quality?
A new strategy to streamline vaccine development and oversight.
From the Editor
Good leaders look beyond industry woes to focus on patients
Burrill on Biotech
Biotech's mid-sized elites position themselves for growth.
Industry and regulators disagree over noncritical parameters.